Pengobatan mutakhir.Kapasitas lokal.

Advanced genomic testing platforms for precision oncology, inherited disease analysis, pathogen sequencing, microbiome analysis and population-level genomic programmes.

Diagnostic testing is regulated differently in every jurisdiction. VectorGene supports local validation and accreditation; the regulatory dossier remains owned by the local institution.

End-to-end support for hospitals and biotechnology organisations to establish CAR-T manufacturing and clinical treatment capability, from GMP facility planning to first clinical use.

CAR-T therapies are approved in several markets for defined indications. Local manufacture and clinical use require approval from the national regulatory authority of the host country, which the local partner owns.

Clinical and translational platforms for immune cell therapy and cellular medicine, available for research collaboration or clinical implementation subject to local regulatory approval.

Most platforms in this group are investigational outside defined trial settings. VectorGene does not present investigational therapies as standard care, and every programme is designed around the host country regulatory framework.

Technology transfer and local implementation support for autologous HSPC gene therapy programmes for transfusion-dependent beta-thalassemia and sickle cell disease.

Gene therapies for beta-thalassemia and sickle cell disease are approved in some markets. Local delivery requires national regulatory clearance, ethics approval and long-term follow-up commitments, all owned by the local institution.

Metagenomic and targeted sequencing platforms for infectious disease diagnosis, outbreak surveillance and microbiome research at institutional or national scale.

Clinical use of metagenomic sequencing is regulated as a diagnostic and varies by jurisdiction. Surveillance and research applications typically sit under different frameworks.

Patient-derived organoid and stem cell platforms for drug screening, treatment response prediction and translational research collaboration.

These platforms are supported for research collaboration and translational study. They are not offered as clinical services, and results are not presented as a basis for treatment decisions outside a trial.